# Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma

> **NCT04888611** · PHASE2 · UNKNOWN · sponsor: **Huashan Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Recurrent Glioblastoma

## Interventions

- **BIOLOGICAL:** Camrelizumab plus GSC-DCV
- **BIOLOGICAL:** Camrelizumab plus Placebo

## Key facts

- **NCT ID:** NCT04888611
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-26
- **Primary completion:** 2023-05-01
- **Final completion:** 2024-05-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-11-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04888611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04888611, "Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT04888611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*